Justin Burgess - Aug 7, 2023 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role
Chief Accounting Officer
Signature
/s/ Justin Burgess
Stock symbol
DVAX
Transactions as of
Aug 7, 2023
Transactions value $
-$51,480
Form type
4
Date filed
8/8/2023, 04:23 PM
Previous filing
Mar 1, 2023
Next filing
Feb 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVAX Common Stock Options Exercise $13.7K +2.53K $5.42 2.53K Aug 7, 2023 Direct
transaction DVAX Common Stock Options Exercise $52.1K +5.53K +218.87% $9.41 8.06K Aug 7, 2023 Direct
transaction DVAX Common Stock Sale -$117K -8.06K -100% $14.55 0 Aug 7, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Stock Option (Right to Buy) Options Exercise -2.53K -100% 0 Aug 7, 2023 Common Stock 2.53K $5.42 Direct F2, F3
transaction DVAX Stock Option (Right to Buy) Options Exercise -5.53K -66.66% 2.77K Aug 7, 2023 Common Stock 5.53K $9.41 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $14.54 to $14.57; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F2 This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 12. 2020, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
F3 Not applicable.
F4 This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 3, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.